• LiveRamp Upgraded to “Buy” at Zacks Investment Research

    24 days ago - By ETF Daily News

    LiveRamp was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Tuesday, Zacks.com reports. The firm presently has a $55.00 price objective on the stock. Zacks Investment Research ‘s target price points to a potential upside of 12.34% from the company's previous close.
    According to Zacks, “LiveRamp Holdings, Inc. operates as a marketing technology company. It provides data foundation, digital transformation, consumer engagement, and online marketing and analysis services. LiveRamp Holdings Inc., formerly known as Acxiom Holdings, is...
    Read more ...

     

  • Lucira Health Upgraded to Buy by Zacks Investment Research

    Lucira Health Upgraded to Buy by Zacks Investment Research

    24 days ago - By ETF Daily News

    Lucira Health was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports. The brokerage currently has a $9.25 target price on the stock. Zacks Investment Research ‘s price target suggests a potential upside of 11.99% from the stock's previous close.
    According to Zacks, “Lucira Health Inc. is a medical technology company. It is focused on the development and commercialization of transformative and infectious disease test kits. Lucira Health Inc. is based in Emeryville, California...
    Read more ...